Days after the FDA approved the blockbuster Lucentis (ranibizumab injection) in a fourth indication – diabetic retinopathy (DR) in patients with diabetic macular edema (DME) – up-and-comer Pfenex Inc. inked a deal with global giant Hospira Inc. to advance its biosimilar competitor, PF582.